Cargando…
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses
The optimum number of treatment courses for younger patients with acute myeloid leukemia (AML) is uncertain. The United Kingdom National Cancer Research Institute AML17 trial randomly assigned patients who were not high risk to a total of three versus four courses. PATIENTS AND METHODS: Patients rec...
Autores principales: | Burnett, Alan K., Russell, Nigel H., Hills, Robert K., Knapper, Stephen, Freeman, Sylvie, Huntly, Brian, Clark, Richard E., Thomas, Ian F., Kjeldsen, Lars, McMullin, Mary Frances, Drummond, Mark, Kell, Jonathan, Spearing, Ruth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177881/ https://www.ncbi.nlm.nih.gov/pubmed/33356418 http://dx.doi.org/10.1200/JCO.20.01170 |
Ejemplares similares
-
P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES
por: Potter, Nicola, et al.
Publicado: (2023) -
Expression of CD33 is a predictive factor for effect of Gemtuzumab Ozogamicin at different doses in adult acute myeloid leukemia
por: Khan, Naeem, et al.
Publicado: (2016) -
The Addition of Arsenic Trioxide to Low Dose Ara-C in Older Patients with AML Does Not Improve Outcome
por: Burnett, Alan K, et al.
Publicado: (2011) -
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
por: Russell, Nigel H., et al.
Publicado: (2021) -
Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial
por: Burnett, Alan K, et al.
Publicado: (2018)